How to state TRL in an ANRF research proposal
How to state TRL in an ANRF proposal: what ATRI and the MAHA MedTech Mission ask for, the evidence reviewers expect at each level, and a model TRL statement.
Part of the guide TRL levels explained: what TRL 1 to 9 really mean, and how to place your technology
An ANRF proposal should state the current TRL, the evidence behind it, the target TRL and the milestones in between. ATRI supports technologies from TRL 4 to TRL 7 and requires at least TRL 4 at entry. The MAHA MedTech Mission call of September 2025 accepted only TRL 3 or above, with uploaded evidence.
The Anusandhan National Research Foundation (ANRF) funds a wide range of research. In its translational programmes, the technology readiness level is no longer a phrase you drop into the introduction. It decides whether you are eligible, how the budget is staged and what reviewers will measure you against for five years.
This guide shows how to state TRL in an ANRF proposal so that it survives scrutiny. It draws on two published ANRF documents: the ATRI initiative page and the MAHA MedTech Mission call for proposals of September 2025.
Where does TRL matter in ANRF calls?
Not every ANRF scheme uses TRL. A basic research grant is judged on the science and may never ask. The translational calls are different.
| Programme | TRL rule | Other key terms |
|---|---|---|
| ANRF Translational Research and Innovation (ATRI) | Entry at least TRL 4; objective is TRL 4 to TRL 7 | Sector centres; at least one committed industry partner; industry pays at least 20% of project cost in cash; five years |
| MAHA MedTech Mission (call of September 2025) | TRL 3 or above, described as a strict criterion with no exceptions | ₹5 crore to ₹25 crore per project, up to ₹50 crore in exceptional cases; 2 to 5 years depending on TRL |
Both share one idea. The TRL you claim at entry, and the TRL you promise at the end, become the yardstick for the project. A wrong claim is costly in either direction: overstate it and reviewers lose trust, understate it and you may be ineligible.
What do the two calls actually ask for?
ATRI. ANRF describes the stage between lab-scale validation (TRL 4) and prototype demonstration in an operational environment (TRL 7) as under-supported, and ATRI is built for it. The page's FAQ says the technology must have reached at least TRL 4, where proof of concept has been validated in a laboratory. Funding is co-funded in two modes: for projects of ₹50 crore to over ₹200 crore, ANRF pays up to 50% or ₹100 crore, whichever is less; for ₹10 crore to ₹50 crore, up to 70% or ₹25 crore, whichever is less. The academic and industry partners must sign an IPR and licensing agreement before the first release of funds.
MAHA MedTech Mission. The concept note format in Annexure I made TRL a structured field. Applicants selected one TRL stage in Question 6, described the supporting documents in Question 21 in no more than 50 words, and uploaded them in Question 22. FAQ 24 said applicants must provide evidence to substantiate the claimed TRL and gave indicative examples tied to CDSCO forms. Section B also asked how much money had been spent to reach the current TRL.
ATRI's window on the TRL scale
What evidence supports each TRL claim?
Reviewers will ask one question of every TRL claim: where is the proof? The MAHA MedTech FAQ gave the clearest Indian example of what counts, for medical devices.
| Claimed TRL | Indicative evidence in the MAHA MedTech call (FAQ 24) |
|---|---|
| TRL 3 | Peer-reviewed publications or third-party technical validation |
| TRL 4 | Acknowledgement of a test licence application on Form MD-12 |
| TRL 5 | Test licence on Form MD-13, and acknowledgement of a clinical investigation application (MD-22; MD-24 for IVDs) |
| TRL 6 | Clinical investigation permission on MD-23 (MD-25 for IVDs) |
| TRL 7 | Acknowledgement of a manufacturing licence application (MD-3 or MD-7) and related import forms for IVDs |
| TRL 8 | Manufacturing licence on MD-5 or MD-9, and import licence where relevant |
| TRL 9 | Post-market surveillance reports |
Outside medical devices, the same principle applies with different documents: test reports, pilot plant runs, field trial data, independent validation. Our post on how to prove your TRL lists evidence by sector.
Where a call gives no definitions, use the National Technology Readiness Assessment Framework from the Office of the Principal Scientific Adviser. It defines TRL 4 as "component and/or system validation in lab" and TRL 7 as "full scale system prototype demonstration in operational environment". It also expects TRL progression timelines to be proposed with a project and reviewed during it, which is exactly how translational funders now behave. NTRAF explained covers the framework in detail.
How do you write the TRL statement?
A good TRL statement fits in half a page and has five parts.
- Current TRL, in one sentence, using the call's definition word for word.
- The evidence, as a short list of documents a reviewer can open: reports, test certificates, publications, licences.
- The critical technology element. Name the part of the system the TRL refers to. A device with a proven sensor and an untested enclosure is not uniformly at one level.
- Target TRL and milestones. For each year, the TRL you expect to reach and the evidence that will show it.
- Risks to progression, with what you will do if a milestone slips.
Five parts of a TRL statement
Here is a model paragraph. It is an illustration with invented details, written for a medical device call.
Current TRL: 4 (component and system validation in the laboratory). Evidence: bench test report of 12 March, independent electrical safety test by an accredited laboratory, and acknowledgement of our MD-12 test licence application. The TRL applies to the sensing module; the enclosure is at TRL 3. Target: TRL 5 by month 12 (MD-13 test licence and simulated-use study), TRL 6 by month 30 (MD-23 permission and pilot clinical investigation). Main risk: delay in clinical investigation permission; mitigation is early pre-submission discussion and a parallel animal study.
Notice what the paragraph avoids: adjectives. Reviewers trust dates, form numbers and named reports.
A worked example of ATRI co-funding
The figures below are an illustration.
An ATRI proposal in Mode I(b) has a total project cost of ₹20 crore.
- ANRF's share is capped at 70% or ₹25 crore, whichever is less: ₹14 crore.
- The industry partner must contribute at least 20% in cash: ₹4 crore.
- The remaining ₹2 crore must come in cash from other non-ANRF sources, such as the institution, a state government or the industry partner again.
The TRL plan drives this budget. Moving from TRL 4 to TRL 7 usually means pilot builds, testing in an operational setting and, for regulated products, approvals. Each of those should appear as a costed milestone. An industry partner putting in ₹4 crore of cash will read the TRL section more closely than any reviewer, because that is where its money turns into a product.
Common mistakes
- Claiming the TRL of the best component for the whole system.
- Quoting a TRL with no document behind it. In the MAHA MedTech call, the evidence upload was part of the form.
- Using one definition set in the proposal and another in the progress report. Pick the call's set and stay with it.
- Promising a jump of three levels in a year with no budget for the testing those levels need.
- Treating TRL as the reviewer's problem. Under ATRI, the industry partner and the IPR agreement depend on it too.
My firm view is that the TRL section is where a proposal earns or loses credibility fastest. A modest, well-evidenced claim of TRL 4 reads far better than an ambitious TRL 6 with nothing attached. The calls themselves will keep changing: ANRF has published separate documents for each programme and each round, so treat the figures here as a guide and the current call document as the rule.
Before you write, check your starting point. In TRL Pro you enter your technology and get back a readiness level from TRL 1 to 9, assessed with Zernyx's own copyrighted framework (ZTRAF) across more than 60 technology domains and subdomains. For the level-by-level picture, see TRL levels explained and our guide to moving from TRL 4 to TRL 6.
Common questions
Does every ANRF scheme ask for a TRL?
No. TRL is central in translational calls such as ATRI and the MAHA MedTech Mission, which fund work towards products. Basic research grants may not ask for it at all. Read the call document for the scheme you are applying to and use its wording.
What TRL does ANRF ATRI require?
ATRI supports technologies from TRL 4 to TRL 7. ANRF's ATRI page says the technology must have reached at least TRL 4, meaning proof of concept validated in a laboratory environment, and the objective is to take it to TRL 7.
What TRL evidence did the MAHA MedTech Mission ask for?
Applicants chose one TRL in Annexure I, described their supporting documents in 50 words and uploaded them. The call's FAQ gave indicative evidence, such as peer-reviewed publications or third-party validation for TRL 3 and acknowledgement of an MD-12 test licence application for TRL 4.
Which TRL definitions should I use in an ANRF proposal?
Use the definitions in the call, if it gives them. If it does not, the National Technology Readiness Assessment Framework published by the Office of the Principal Scientific Adviser gives a common Indian set of TRL 1 to 9 definitions.